Identification and Initial Validation of Neuroendocrine Differentiation as a Novel Prognostic Factor in Stage II Colorectal Cancer Patients
Oncology · 2024
DOI: 10.1159/000540936 ↗Kurz gefasst
Fachartikel in der Zeitschrift Oncology, 2024. Verfasst von Yu Liang und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Colorectal Surgery, Liaoning Cancer Hospital and Institute, Cancer Hospital of China Medical University, Shenyang, China. Hauptthemen laut MEDLINE: Colorectal Neoplasms, Chromogranin A. Die Arbeit nennt 18 Literaturangaben.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Introduction
Neuroendocrine differentiation is often found in colorectal cancer, but its impact on prognosis remains controversial. This study explored the association between neuroendocrine differentiation and prognosis in stage II/III colorectal cancer patients.
Methods
Between 2012 and 2018, a total of 3,441 stage II/III colorectal cancer patients were included for analysis. To verify neuroendocrine differentiation, immunohistochemistry was performed to explore the expression of chromogranin A and synaptophysin in colorectal cancer. In addition, the difference in overall survival between groups was analyzed. A Kaplan-Meier analysis was used to determine the clinicopathological characteristics significantly correlated with survival, and a Cox proportional hazards analysis was used to identify factors independently affecting overall survival prognosis. Furthermore, the findings were validated by the Gene Expression Omnibus database.
Results
Among the 3,441 stage II/III colorectal cancer patients, in comparison to patients with neuroendocrine differentiation (+), patients with neuroendocrine differentiation (+) had a poorer prognosis (p = 0.001). Furthermore, multivariate survival analysis of stage II cases revealed that tumor differentiation (p = 0.018), nerve invasion (p < 0.001), and neuroendocrine differentiation (+) (p = 0.002) were independent prognostic factors. Moreover, the prognosis of patients with neuroendocrine differentiation (+) was similar to that of patients with high-risk factors in stage II cases (p = 0.639). High chromogranin A expression was correlated with poor prognosis in stage II colorectal cancer patients in the Gene Expression Omnibus database (p < 0.001).
Conclusion
The prognosis of colorectal cancer with neuroendocrine differentiation (+) was poor, especially in stage II colorectal cancer patients. Neuroendocrine differentiation might be another high-risk factor for the prognosis of stage II colorectal cancer patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Colorectal Surgery, Liaoning Cancer Hospital and Institute, Cancer Hospital of China Medical University, Shenyang, China.
- Department of Gastric Surgery, Liaoning Cancer Hospital and Institute, Cancer Hospital of China Medical University, Shenyang, China.
- The Liaoning Provincial Key Laboratory of Interdisciplinary Research on Gastrointestinal Tumor Combining Medicine with Engineering, Shenyang, China.
- Department of Anesthesiology, Liaoning Cancer Hospital and Institute, Cancer Hospital of China Medical University, Shenyang, China.
Zitieren
APA
Liang, Y., Li, Y., Guo, R., Zhao, Y., Miao, H., Chang, H., & Chen, Y. (2024). Identification and Initial Validation of Neuroendocrine Differentiation as a Novel Prognostic Factor in Stage II Colorectal Cancer Patients. Oncology. https://doi.org/10.1159/000540936
Vancouver
Liang Y, Li Y, Guo R, Zhao Y, Miao H, Chang H, et al. Identification and Initial Validation of Neuroendocrine Differentiation as a Novel Prognostic Factor in Stage II Colorectal Cancer Patients. Oncology. 2024. doi:10.1159/000540936
BibTeX
@article{Liang2024,
author = {Liang, Yu and Li, Yongmin and Guo, Rui and Zhao, Yan and Miao, Huanshuo and Chang, Hong and Chen, Yue},
title = {Identification and Initial Validation of Neuroendocrine Differentiation as a Novel Prognostic Factor in Stage II Colorectal Cancer Patients},
journal = {Oncology},
year = {2024},
doi = {10.1159/000540936}
}
EUVIMED